Jennifer Hughes, NP
Psychiatric/Mental Health · Columbus, OHNPI 1700211646
Payments from drug & device makers
Across 66 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$273
- AbbVie$233
- Alkermes, Inc.$119
- Astellas Pharma US Inc$100
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$80
- Lundbeck LLC$73
- plus $366 from 13 others
What the payments were for
- Food & beverage$1,17094%
- Education$766%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 14 | $273 |
| AbbVie | 14 | $233 |
| Alkermes, Inc. | 6 | $119 |
| Astellas Pharma US Inc | 2 | $100 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $80 |
| Lundbeck LLC | 5 | $73 |
| Sunovion Pharmaceuticals Inc. | 4 | $67 |
| Johnson & Johnson | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Neurocrine Biosciences, Inc. | 2 | $36 |
| Eisai Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Neos Therapeutics, LP | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $14 |
How this compares
$1,246 in reported general payments places this provider in the 60th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 76 | $221,804 |
| AristadaAripiprazole Lauroxil | 22 | $75,831 |
| VraylarCariprazine Hcl | 44 | $63,546 |
| PerserisRisperidone | 12 | $32,558 |
| CaplytaLumateperone Tosylate | 12 | $22,738 |
| Aripiprazole | 96 | $16,958 |
| RexultiBrexpiprazole | 11 | $15,941 |
| Lurasidone Hcl | 39 | $3,833 |
| Divalproex Sodium ErDivalproex Sodium | 77 | $3,699 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 18 | $2,949 |
| Haloperidol Decanoate | 66 | $2,790 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 27 | $2,601 |
| Chlorpromazine Hcl | 13 | $2,505 |
| Ziprasidone Hcl | 46 | $2,493 |
| Quetiapine Fumarate | 149 | $2,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $58 | $221,80476 claims |
| Alkermes, Inc.Aristada | $119 | $75,83122 claims |
| AbbVieVraylar | $233 | $63,54644 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $80 | $22,73812 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $273 | $15,94111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Columbus
- Holly SchweitzerColumbus$78K
- David HuffmanColumbus$50K
- Tarsicio GacheruColumbus$18K
- Alicja MatusiakColumbus$11K
- Summer LawsonColumbus$11K
- Gregory BlankenshipColumbus$10K
- Jennifer WilsonColumbus$10K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.